Personalized Medicine Are we there yet?

Bruce McManus Heart + Lung FEST 2011 – Best Practices in Personalized Medicine Tools for Personalized Medicine

Tuesday, March 8, 2011









The News – Hype or Hope?



THE EVIDENCE GAP Patient's DNA May Be Signal to Tailor Me

BEHAVIOR

By ANDREW POLLAC Published: December



Imagine that you are depressed and see a new that you have clinical dep antidepressant. So far, so g 60 percent chance that vo that it could take as long a which time you'll probably

By RICHARD A. FRIEDMAN, M.D.

Published: June 19, 2007

Enlarge This Im:

Dr. David Flockhart dis the body converted th

The Evidence (The Genetic Fac Articles in this ser exploring medical used despite scant they work and are steps toward medi evidence.

David '

Government Gouvernement du Canada of Canada

Newsweek Q Search

NATION · POLITICS · WORLD · BUSINESS/TECH · CULTURE · LIFE/H

SUBSCRIBE | LOGIN · REGISTER | BLOGS: THE GAGGLE · DECLASSIFIED · TECHTONIC SHIFTS · HUMAN CONDITION · MO

MEDICINE TAILORED JUST FOR YOU

On the Horizon, Personalized GENETIC TESTS WILL TELL YOU WHICH LIFESTYLE CHANGES ARE CRUCIAL FOR YOU, AND WHICH DRUGS MIGHT WORK BEST FOR YO DISEASE--WITH THE FEWEST SIDE EFFECTS



Andy Murray fac Patients who need drug treatment could be given individually foos: only two ring a saliva-based genetic the second se



DNA Is Part of the Story



PROOF Centre of | Centre d' EXCELLENCE





How Can We Do Better?

BACK

NEXT



Whenever critics complain about the high cost of prescription drugs, the pharmaceutical industry's standard defense is that companies have to plow so much money into researching innovative new medicines. But a recently released report from the Government Accountability Office casts doubt on that rationale. Yes the industry is spending heavily on R&D, the GAO found, but it turns out big pharma isn't actually generating such a good return on their investments.

or the companies that make known as cox-2 inhibitors pular Vioxx was pulled from ttack and stroke. A er, leaving only Pfizer's tly done wonders for that ine months of this year, first batch of what could be

Gouvernement Government Canada du Canada

PROOF Centre of | Centre d' EXCELLENCE





Dizzying Potential in Oncology

REUTERS

UPDATE 1-FDA OKs expanded use of Glaxo breast cancer

drug

Fri. Jan 29 2010

* Tykerb approved in combination with Fem * For use in HER2-positive, hormone positi NEW YORK, Jan 29 (Reuters) - U.S. health saying it can now be used in combination w The Food and Drug Administration said the post-menopausal women for whom hormo HER2 is a protein involved in normal cell gr have been found to be effective only in wom In hormone positive breast cancer, the pres Tykerb, a pill, works by depriving tumor cells It was initially approved for use in combinat treatment with other chemotherapy agents : "This drug combination of Tykerb plus Fem Richard Pazdur, the FDA's director of the Of The approval was based on a study in whic research shows. compared with 13 weeks for women who re



EXECUTIVE HEALTH January 29, 2010, 06:00 EST

Herceptin Again Proves Mettle Against Breast Cancer

Improved survival seen when used with chemo for HER2 malignancies, researchers report

By Amanda Gardner HealthDay Reporter

THURSDAY, Jan. 28 (HealthDay News

"It's in a European journal [The Lancet Baton Rouge, La. "It just confirms what

"The reason why Herceptin is so valua spread to the lymph nodes in the armp

When Brooks sees a patient with locall



Breast Cancer Breakthrough Test to Identify Best Treatments

Tuesday, February 02, 2010

NewsCORE

A simple test could soon identify whether women with breast cancer would benefit from certain ADVERTISEME types of treatment, The Sun reported Tuesday.

Scientists at Queen's University in Belfast discovered that those with high levels of the gene FKBPL are more likely to respond to commonly-used drug tamoxifen.

It is estimated that only around two-thirds of those who use the drug actually benefit from it.

The breakthrough could stop thousands of women needlessly experiencing side effects when tamoxifen might not work.



Gouvernement Government of Canada du Canada



The Canadian Scene





Ethical and privacy issues
Added costs for counseling

Follow-up for genetic counseling
Educational gaps in professions, public and media

Direct-to-consumer advertising

Genetic services

PROOF Centre of | Centre d' EXCELLENCE







"It is much more important to know what kind of patient has a disease than to know what kind of disease a patient has"

~ Caleb Parry, 18th Century physician, Bath

bruce.mcmanus@hli.ubc.ca www.proofcentre.ca



Government Gouvernement of Canada du Canada



